Johnson and Johnson (NYSE: JNJ) has gained some ground in the coronavirus vaccine race. The pharmaceutical and consumer goods company announced Thursday that, in preclinical studies, its candidate for the Ad26.COV2-S vaccine had been shown to be effective in protecting nonhuman primates from SARS-CoV-2 infection.
In contrast to other candidates for coronavirus vaccine, such as what many observers consider the most promising, ModernmRNA-1273 – Johnson & Johnson produced its response with a single dose.
Based on these results, Johnson & Johnson has begun testing its human candidate in phase 1 / 2a clinical trials in the United States and Belgium. For these studies, Ad26.COV2-S will be administered in single-dose and single-dose regimens; the company will use the tests to assess its safety, immunogenicity (the ability to produce an immune response) and potential to cause adverse reactions.
More than 1,000 healthy adults between the ages of 18 and 55 will take part in the test, plus a cohort aged 65 and over. The company also plans to conduct a phase 2 trial in the Netherlands, Spain and Germany, and a phase 1 study in Japan.
Johnson & Johnson aims to advance Ad26.COV2-S through the clinical study process at some speed. “The findings give us confidence as we advance our vaccine development and luxury manufacturing in parallel, having started a phase 1 / 2nd trial in July with the intention of moving on to a phase 3 trial in the September, ”said scientific director Paul Stoffels.
A number of large pharmaceutical companies, as well as numerous biotech companies, are developing candidates for vaccine, drugs or both to combat COVID-19. But while a couple of drugs have shown some promise as treatments for the new coronavirus, no vaccine candidate for this test has proven effective in a phase 3 trial, the key step before it could be obtained. regulatory approval and put on the market for the public.
On Thursday, Johnson & Johnson shares reduced the bearish market downtrend, albeit by only 2%.